Maya Rios

Maya Rios

Energy & Utilities Analyst

Energy & utilities analyst with a background in power markets and project finance. Previously worked on renewable development underwriting and utility rate-case analysis. Covers oil & gas, midstream, and power/renewables with emphasis on cash flow durability, commodity sensitivity, and balance sheet risk.

Articles 707

Feb 5, 2026 Finance

UK Aviation Regulator Questions Air India Over Boeing 787 Fuel Control Issue

Civil Aviation Authority Requests Detailed Maintenance Data Following Fuel Switch Malfunction

The UK Civil Aviation Authority (CAA) has formally contacted Air India to clarify a reported malfunction involving the fuel control switch on a Boeing...

Feb 5, 2026 Trade Ideas

AbbVie: Immunology Momentum + Reliable Cash Flow — A Tactical Long on the Dip

Skyrizi and Rinvoq are driving growth; buy a disciplined pullback for yield and upside.

AbbVie is benefitting from accelerating Skyrizi and Rinvoq sales even as legacy Humira growth slows. Cash flow remains strong (operating cash flow of ...

Trade Idea Long
Feb 5, 2026 Finance

Alphabet Surpasses Expectations While Amazon, Bristol-Myers, and ConocoPhillips Await Earnings Reports

Mixed futures mark the market as key earnings releases and corporate actions unfold

As U.S. stock futures exhibit mixed trends, several significant corporate earnings as well as restructuring announcements are poised to influence inve...

Feb 5, 2026 Finance

C3is Inc. Sees Significant After-Hours Surge Amid Ownership Disclosure by Imperial Petroleum

Stock Jumps Nearly 29% Following SEC Filing Detailing Imperial Petroleum’s Majority Stake in C3is

Shares of C3is Inc. experienced a notable increase in after-hours trading, rising by nearly 29% after a regulatory filing revealed that Imperial Petro...

Senators Push Back Against Presidential Proposal to Federalize Elections
Feb 5, 2026 Business News

Senators Push Back Against Presidential Proposal to Federalize Elections

Bipartisan voices affirm state control of voting processes in line with constitutional provisions

A debate has unfolded within U.S. political leadership following a suggestion from the president advocating for increased federal oversight in electio...

Senator Elizabeth Warren Challenges OpenAI's Financial Strategies and Taxpayer Risk
Feb 4, 2026 Finance

Senator Elizabeth Warren Challenges OpenAI's Financial Strategies and Taxpayer Risk

Concerns mount over OpenAI's high compensation and potential reliance on government support amid rapid expansion

Senator Elizabeth Warren has raised significant concerns about OpenAI's financial management and its potential expectation of government financial sup...

Feb 4, 2026 Finance

Alphabet, Qualcomm, Arm, Broadcom, and Snap Capture Investor Focus Amid Mixed Market Activity

Key technology stocks show divergent moves following earnings reports and outlooks, triggering varied market reactions

U.S. stock indices delivered mixed performances Wednesday, with the Dow Jones rising, while the S&P 500 and Nasdaq declined. Investor attention center...

Feb 4, 2026 Trade Ideas

First Financial (FFBC) - Clean Fundamentals, Cheap Multiple, Dividends and a Clear Trade Setup

A regional bank with improving earnings, strong capitalization and a 3%-plus yield - tactical long with defined stops and targets.

First Financial Bancorp (FFBC) looks like a pragmatic long: consistent quarterly profits, a well-capitalized balance sheet, a rising quarterly dividen...

Trade Idea Long
Feb 4, 2026 Finance

AMD Shares Tumble on Q4 Earnings Fueled by One-Off China Sales and Tepid Q1 Guidance

Despite Record Revenues, Market Reacts Negatively to Non-recurrent China Boost and Slowing Growth Trajectory

Advanced Micro Devices (AMD) experienced a sharp decline in its stock price following its Q4 earnings release, which showcased record revenue figures ...

Feb 4, 2026 Finance

Eli Lilly Gains Momentum Over Novo Nordisk in 2026 Weight Loss Drug Market Competition

Strong earnings forecast puts Eli Lilly ahead as Novo Nordisk revises down 2026 sales outlook

Eli Lilly's recent financial results and optimistic guidance for fiscal 2026 have propelled it ahead of rival Novo Nordisk, which has lowered its sale...